IDX184

Research use only, not for human use.

IDX184 is a potent, orally active, targeted HCV polymerase inhibitor and nucleoside polymerase.IDX184 effectively inhibits HCV polymerase (IC50=0.31 μM, Ki=52.3 nM).

IDX184 is a potent and orally bioavailable inhibitor of HCV replication. IDX184 potently inhibits HCV polymerase (IC50=0.31 μM, Ki=52.3 nM).

IDX184 is a liver-targeted prodrug of the nucleotide 2′-MeG-MP. IDX184 is a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus.IDX184 is a second generation, orally bioavailable nucleotide prodrug designed to provide increased anti-HCV efficacy and safety versus the parent nucleoside. In HCV replicon testing, IDX184 is the most potent inhibitor (EC50=0.3-0.45 μM) compared to any of the 2’ or 4’ modified nucleosides (EC50=4-6 μM) and is also highly inhibitory in the JFH-1 infectious system (EC50=0.06-0.11 μM). IDX184 is not toxic (CC50>100μM) in any tested cell line.

——

——

Others

Other Targets

HCV Protease

——

——

1036915-08-8

626.62

C25H35N6O9PS

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (398.97 mM; Ultrasonic )

C[C@]1(O)[C@H](N2C3=C(N=C2)C(=O)N=C(N)N3)O[C@H](COP(NCC4=CC=CC=C4)(OCCSC(C(CO)(C)C)=O)=O)[C@H]1O

——

(-20℃)

With Ice Pack

≥ 2 years